MA40887A - Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant - Google Patents
Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenantInfo
- Publication number
- MA40887A MA40887A MA040887A MA40887A MA40887A MA 40887 A MA40887 A MA 40887A MA 040887 A MA040887 A MA 040887A MA 40887 A MA40887 A MA 40887A MA 40887 A MA40887 A MA 40887A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutically acceptable
- methoxy
- pyrrole
- acceptable salts
- derivatives
- Prior art date
Links
- OTODBDQJLMYYKQ-UHFFFAOYSA-N 3-methoxy-1h-pyrrole Chemical class COC=1C=CNC=1 OTODBDQJLMYYKQ-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
<!--startfragment-->la présente invention concerne un dérivé de 4-méthoxy pyrrole ou son sel pharmaceutiquement acceptable, son procédé de préparation, et une composition pharmaceutique le comprenant. Les dérivés de 4-méthoxy pyrrole ou leurs sels pharmaceutiquement acceptables selon la présente invention présentent non seulement d'excellents effets en matière d'activité inhibitrice de la pompe à protons, d'activité d'inhibition de lésions gastriques et d'amélioration de facteur défensif, mais également une excellente activité d'éradication contre <em>h. Pylori</em>. Par conséquent, les dérivés de pyrrole 4-méthoxy ou leurs sels pharmaceutiquement acceptables peuvent être utilisés efficacement pour la prévention et le traitement de lésions gastro-intestinales dues à un ulcère du tractus gastro-intestinal, une gastrite, une œsophagite par reflux ou <em>h. Pylori</em>. De plus, les dérivés de pyrrole 4-méthoxy ou leurs sels pharmaceutiquement acceptables présentent des activités inhibitrices contre gpcr et peuvent donc être utilisés efficacement pour la prévention et le traitement de maladies induites par le récepteur 5-ht ou le récepteur muscarinique de l'acétylcholine.<!--endfragment-->
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150058712 | 2015-04-27 | ||
| PCT/KR2016/004411 WO2016175555A2 (fr) | 2015-04-27 | 2016-04-27 | Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant |
| EP16786741.5A EP3197867B1 (fr) | 2015-04-27 | 2016-04-27 | Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40887A true MA40887A (fr) | 2017-08-02 |
| MA40887B1 MA40887B1 (fr) | 2019-01-31 |
Family
ID=55916928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40887A MA40887B1 (fr) | 2015-04-27 | 2016-04-27 | Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10100010B1 (fr) |
| EP (1) | EP3197867B1 (fr) |
| JP (1) | JP6244498B1 (fr) |
| KR (2) | KR101613245B1 (fr) |
| CN (1) | CN107001263B (fr) |
| AU (1) | AU2016255308B2 (fr) |
| CA (1) | CA2977750C (fr) |
| CL (1) | CL2017002571A1 (fr) |
| CO (1) | CO2017010539A2 (fr) |
| DO (2) | DOP2017000230A (fr) |
| EC (1) | ECSP17071036A (fr) |
| ES (1) | ES2703709T3 (fr) |
| HR (1) | HRP20182066T1 (fr) |
| HU (1) | HUE042449T2 (fr) |
| MA (1) | MA40887B1 (fr) |
| MX (1) | MX2017012507A (fr) |
| MY (1) | MY193257A (fr) |
| NZ (1) | NZ734896A (fr) |
| PE (1) | PE20180022A1 (fr) |
| PH (1) | PH12017501755B1 (fr) |
| PL (1) | PL3197867T3 (fr) |
| PT (1) | PT3197867T (fr) |
| RS (1) | RS58076B1 (fr) |
| RU (1) | RU2663895C1 (fr) |
| SA (1) | SA517390127B1 (fr) |
| SG (1) | SG11201706877RA (fr) |
| SI (1) | SI3197867T1 (fr) |
| TN (1) | TN2017000424A1 (fr) |
| WO (1) | WO2016175555A2 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017164575A1 (fr) * | 2016-03-25 | 2017-09-28 | Daewoong Pharmaceutical Co.,Ltd. | Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
| KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) * | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| WO2020060213A1 (fr) | 2018-09-19 | 2020-03-26 | 주식회사 대웅제약 | Procédé de production d'un dérivé de 4-méthoxy pyrrole |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| KR102570011B1 (ko) * | 2019-12-18 | 2023-08-23 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물 |
| AU2021293694B2 (en) * | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
| WO2022051979A1 (fr) * | 2020-09-10 | 2022-03-17 | 广东莱佛士制药技术有限公司 | Procédé de préparation d'intermédiaire de bloqueur compétitif d'ions de potassium |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| CR20230266A (es) | 2020-12-18 | 2023-07-19 | Daewoong Pharmaceutical Co Ltd | Nueva formulación para administración oral, que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina |
| PH12023553209A1 (en) | 2021-05-26 | 2024-02-19 | Daewoong Pharmaceutical Co Ltd | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| TWI892291B (zh) * | 2021-05-26 | 2025-08-01 | 南韓商大熊製藥股份有限公司 | 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器 |
| JP7802829B2 (ja) | 2021-05-26 | 2026-01-20 | デウン ファーマシューティカル カンパニー リミテッド | １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な注射用製剤 |
| KR102556500B1 (ko) * | 2021-11-19 | 2023-07-19 | 하나제약 주식회사 | 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물 |
| CN118541361A (zh) * | 2021-12-15 | 2024-08-23 | 日东制药株式会社 | 1-磺酰基吡咯衍生物的新型盐、其制备方法和包括其的药物组合物 |
| WO2023113458A1 (fr) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Nouveau sel de dérivé de 1-sulfonyle pyrrole, son procédé de préparation et composition pharmaceutique le comprenant |
| US20240415808A1 (en) | 2021-12-15 | 2024-12-19 | Daewoong Pharmaceutical Co., Ltd. | Dosage Regimen for Fexuprazan Injection Composition |
| KR20230102353A (ko) | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
| WO2023211843A1 (fr) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Bloqueurs d'acide compétitif pour le potassium pour le traitement d'états hypersécrétoires pathologiques |
| TW202411215A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| TW202411216A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
| CN115557876A (zh) * | 2022-10-26 | 2023-01-03 | 四川国康药业有限公司 | 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途 |
| CR20250335A (es) | 2023-02-15 | 2025-09-23 | Daewoong Pharmaceutical Co Ltd | Procedimiento de fabricación de derivados de 4-metoxipirrol |
| KR20250124776A (ko) * | 2024-02-13 | 2025-08-20 | 유노비아 주식회사 | 6-메톡시피리딘-3-일 유도체를 포함하는 위장관 질환의 치료 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04004464A (es) | 2001-11-08 | 2004-08-11 | Upjohn Co | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. |
| BR0313396A (pt) | 2002-08-12 | 2005-06-28 | Sugen Inc | 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| MX2007002274A (es) | 2004-08-23 | 2007-05-07 | Lilly Co Eli | Agentes del receptor de histamina h3. preparacion y usos terapeuticos. |
| WO2006025716A1 (fr) | 2004-09-03 | 2006-03-09 | Yuhan Corporation | Derives de pyrrolo[2,3-c]pyridine et leurs procedes de preparation |
| KR101178747B1 (ko) | 2004-09-30 | 2012-09-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 프로톤 펌프 저해제 |
| ES2359725T3 (es) | 2004-09-30 | 2011-05-26 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos. |
| HRP20110473T1 (hr) | 2005-08-30 | 2011-07-31 | Takeda Pharmaceutical Company Limited | Supstituirani derivati 1-heterociklilsulfonil, 2-aminometil, 5-(hetero)-aril 1-h-pirola kao inhibitori kiselinske sekrecije |
| DE102005041246A1 (de) | 2005-08-31 | 2007-03-08 | Basf Coatings Ag | Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| KR101088247B1 (ko) | 2005-12-19 | 2011-11-30 | 라퀄리아 파마 인코포레이티드 | 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도 |
| KR20090013815A (ko) | 2006-05-04 | 2009-02-05 | 솔베이 파마슈티칼스 비. 브이 | 충동 조절 장애의 치료를 위한 무스카린 작용제 |
| DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2008131779A1 (fr) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Dérivés d'isoquinolinone utilisés en tant qu'antagonistes de nk3 |
| EP2560676B8 (fr) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Composés organiques |
| JP6292736B2 (ja) * | 2012-11-19 | 2018-03-14 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | ピロールスルホンアミド誘導体、その製造法およびその医療用途 |
| AU2014240139A1 (en) | 2013-03-15 | 2015-09-17 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| ITBS20130175A1 (it) | 2013-11-22 | 2015-05-23 | Ind Saleri Italo Spa | Gruppo pompa di raffreddamento regolabile con girante regolabile |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| CN104447191B (zh) | 2014-10-30 | 2016-03-23 | 绵阳达高特新材料有限公司 | 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
-
2016
- 2016-02-03 KR KR1020160013588A patent/KR101613245B1/ko active Active
- 2016-04-08 KR KR1020160043522A patent/KR101818704B1/ko active Active
- 2016-04-27 WO PCT/KR2016/004411 patent/WO2016175555A2/fr not_active Ceased
- 2016-04-27 PL PL16786741T patent/PL3197867T3/pl unknown
- 2016-04-27 JP JP2017531371A patent/JP6244498B1/ja active Active
- 2016-04-27 CA CA2977750A patent/CA2977750C/fr active Active
- 2016-04-27 AU AU2016255308A patent/AU2016255308B2/en active Active
- 2016-04-27 US US15/520,518 patent/US10100010B1/en active Active
- 2016-04-27 NZ NZ734896A patent/NZ734896A/en unknown
- 2016-04-27 MX MX2017012507A patent/MX2017012507A/es active IP Right Grant
- 2016-04-27 MA MA40887A patent/MA40887B1/fr unknown
- 2016-04-27 EP EP16786741.5A patent/EP3197867B1/fr active Active
- 2016-04-27 TN TNP/2017/000424A patent/TN2017000424A1/en unknown
- 2016-04-27 RU RU2017133866A patent/RU2663895C1/ru active
- 2016-04-27 CN CN201680003652.8A patent/CN107001263B/zh active Active
- 2016-04-27 PT PT16786741T patent/PT3197867T/pt unknown
- 2016-04-27 ES ES16786741T patent/ES2703709T3/es active Active
- 2016-04-27 PH PH1/2017/501755A patent/PH12017501755B1/en unknown
- 2016-04-27 PE PE2017001632A patent/PE20180022A1/es unknown
- 2016-04-27 RS RS20181555A patent/RS58076B1/sr unknown
- 2016-04-27 SG SG11201706877RA patent/SG11201706877RA/en unknown
- 2016-04-27 SI SI201630148T patent/SI3197867T1/sl unknown
- 2016-04-27 HU HUE16786741A patent/HUE042449T2/hu unknown
- 2016-04-27 HR HRP20182066TT patent/HRP20182066T1/hr unknown
- 2016-04-27 MY MYPI2017703532A patent/MY193257A/en unknown
-
2017
- 2017-10-03 DO DO2017000230A patent/DOP2017000230A/es unknown
- 2017-10-10 SA SA517390127A patent/SA517390127B1/ar unknown
- 2017-10-11 CL CL2017002571A patent/CL2017002571A1/es unknown
- 2017-10-13 CO CONC2017/0010539A patent/CO2017010539A2/es unknown
- 2017-10-25 EC ECIEPI201771036A patent/ECSP17071036A/es unknown
-
2021
- 2021-10-18 DO DO2021000213A patent/DOP2021000213A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40887A (fr) | Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| WO2011027249A3 (fr) | Dérivés de benzimidazole | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA31766B1 (fr) | Composés organiques | |
| EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
| WO2009082819A8 (fr) | Nouveaux dérivés de lupane | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| UA103272C2 (uk) | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 | |
| EA200971104A1 (ru) | Производные бензимидазола | |
| WO2009036996A3 (fr) | Antagoniste de faible masse moléculaire du récepteur b1 de la bradykinine | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| MA43468B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| WO2020190890A8 (fr) | Dérivés de nicorandil | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| FR3047665B1 (fr) | Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees | |
| ZA202204251B (en) | Compounds and compositions for the treatment of parasitic diseases | |
| WO2008121859A8 (fr) | Procédés d'utilisation de composés tricycliques dans le traitement de maladies ou d'affections véhiculées par canal sodique | |
| WO2019039836A3 (fr) | Composition de formulation complexe pour le traitement d'une maladie neurodégénérative | |
| Zádori et al. | Dual alpha2C/5HT1A receptor agonist allyphenyline induces gastroprotection and inhibits fundic and colonic contractility |